Collectively, our data reveal a previously unappreciated role for UGDH and UDP-GlcA in NASH pathogenesis by controlling RIPK1 activation and hepatocyte apoptosis, and suggest UDP-GlcA metabolism as a feasible target for more specific treatment of NASH-associated liver damage. This evidence concerns the gene UGDH and metabolic dysfunction-associated steatohepatitis.